Betul Berber1, Rafael Ibarra1, Laura Snyder1, Min Yao2, Jeffrey Fabien2, Michael T Milano3, Alan W Katz3, Karyn Goodman4, Kevin Stephans5, Galal El-Gazzaz6, Federico Aucejo6, Charles Miller6, John Fung6, Simon Lo2, Mitchell Machtay2, Juan Sanabria1. 1. Department of Surgery, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH, USA. 2. Department of Radiation Oncology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH, USA. 3. Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA. 4. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 5. Department of Radiation Oncology, Cleveland Clinic Foundation, Lerner College, Cleveland, OH, USA. 6. Department of Surgery, Cleveland Clinic Foundation, Lerner College, Cleveland, OH, USA.
Abstract
BACKGROUND: Surgical resection is the standard treatment for liver metastases, although for the majority of patients this is not possible. Stereotactic body radiotherapy (SBRT) is an alternative local-regional therapy. The purpose of this study was to evaluate the results of SBRT for secondary liver tumours from a combined multicentre database. METHODS: Variables from patients treated with SBRT from four Academic Medical Centres were entered into a common database. Local tumour control and 1-year survival rates were calculated. RESULTS: In total, 153 patients (91 women) 59 ± 8.4 years old with 363 metastatic liver lesions were treated with SBRT. The underlying primary tumour arose from gastrointestinal (GI), retroperitoneal and from extra-abdominal primaries in 56%, 8% and 36% of patients, respectively. Metastases, with a gross tumour volume (GTV) of 138.5 ± 126.8 cm(3) , were treated with a total radiation dose of 37.5 ± 8.2 Gy in 5 ± 3 fractions. The 1-year overall survival was 51% with an overall local control rate of 62% at a mean follow-up of 25.2 ± 5.9 months. A complete tumour response was observed in 32% of patients. Grade 3-5 adverse events were noted in 3% of patients. CONCLUSION: Secondary liver tumours treated with SBRT had a high rate of local control with a low incidence of adverse events.
BACKGROUND: Surgical resection is the standard treatment for liver metastases, although for the majority of patients this is not possible. Stereotactic body radiotherapy (SBRT) is an alternative local-regional therapy. The purpose of this study was to evaluate the results of SBRT for secondary liver tumours from a combined multicentre database. METHODS: Variables from patients treated with SBRT from four Academic Medical Centres were entered into a common database. Local tumour control and 1-year survival rates were calculated. RESULTS: In total, 153 patients (91 women) 59 ± 8.4 years old with 363 metastatic liver lesions were treated with SBRT. The underlying primary tumour arose from gastrointestinal (GI), retroperitoneal and from extra-abdominal primaries in 56%, 8% and 36% of patients, respectively. Metastases, with a gross tumour volume (GTV) of 138.5 ± 126.8 cm(3) , were treated with a total radiation dose of 37.5 ± 8.2 Gy in 5 ± 3 fractions. The 1-year overall survival was 51% with an overall local control rate of 62% at a mean follow-up of 25.2 ± 5.9 months. A complete tumour response was observed in 32% of patients. Grade 3-5 adverse events were noted in 3% of patients. CONCLUSION: Secondary liver tumours treated with SBRT had a high rate of local control with a low incidence of adverse events.
Authors: Robert McCammon; Tracey E Schefter; Laurie E Gaspar; Rebekah Zaemisch; Daniel Gravdahl; Brian Kavanagh Journal: Int J Radiat Oncol Biol Phys Date: 2008-09-09 Impact factor: 7.038
Authors: Karyn A Goodman; Ellen A Wiegner; Katherine E Maturen; Zhigang Zhang; Qianxing Mo; George Yang; Iris C Gibbs; George A Fisher; Albert C Koong Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-28 Impact factor: 7.038
Authors: Alan W Katz; Madeleine Carey-Sampson; Ann G Muhs; Michael T Milano; Michael C Schell; Paul Okunieff Journal: Int J Radiat Oncol Biol Phys Date: 2006-12-29 Impact factor: 7.038
Authors: B Engels; H Everaert; T Gevaert; M Duchateau; B Neyns; A Sermeus; K Tournel; D Verellen; G Storme; M De Ridder Journal: Ann Oncol Date: 2010-08-04 Impact factor: 32.976
Authors: David L Andolino; Cynthia S Johnson; Mary Maluccio; Paul Kwo; A Joseph Tector; Jennifer Zook; Peter A S Johnstone; Higinia R Cardenes Journal: Int J Radiat Oncol Biol Phys Date: 2011-06-07 Impact factor: 7.038
Authors: Mi-Sook Kim; Sung Yul Yoo; Chul Koo Cho; Hyung Jun Yoo; Chul Won Choi; Young Seok Seo; Jin Kyu Kang; Dong Han Lee; Dae Yong Hwang; Sun Mi Moon; Min Suk Kim; Hye Jin Kang; Young Han Kim Journal: Oncology Date: 2009-02-13 Impact factor: 2.935
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Michael T Milano; Alan W Katz; Ann G Muhs; Abraham Philip; Daniel J Buchholz; Michael C Schell; Paul Okunieff Journal: Cancer Date: 2008-02-01 Impact factor: 6.860
Authors: A E M van der Pool; A Méndez Romero; W Wunderink; B J Heijmen; P C Levendag; C Verhoef; J N M Ijzermans Journal: Br J Surg Date: 2010-03 Impact factor: 6.939
Authors: Carmen Rubio; Ovidio Hernando-Requejo; Daniel Zucca Aparicio; María ALlona Krauel; Mercedes López Gonzalez; Juan María Pérez; Emilio Sánchez Saugar; Pedro Fernández Letón Journal: Rep Pract Oncol Radiother Date: 2016-09-17
Authors: Kenneth W Merrell; Jedediah E Johnson; Benjamin Mou; Brandon M Barney; Kathryn E Nelson; Charles S Mayo; Michael G Haddock; Christopher L Hallemeier; Kenneth R Olivier Journal: J Radiosurg SBRT Date: 2016
Authors: Nicolaus Hj Andratschke; Carsten Nieder; Franz Heppt; Michael Molls; Frank Zimmermann Journal: Radiat Oncol Date: 2015-03-20 Impact factor: 3.481
Authors: Debnarayan Dutta; Sathiya Krishnamoorthy; H Sudahar; M Muthukumaran; T Ramkumar; Jayraj Govindraj Journal: South Asian J Cancer Date: 2018 Jul-Sep
Authors: Sanne Nieuwenhuizen; Madelon Dijkstra; Robbert S Puijk; Bart Geboers; Alette H Ruarus; Evelien A Schouten; Karin Nielsen; Jan J J de Vries; Anna M E Bruynzeel; Hester J Scheffer; M Petrousjka van den Tol; Cornelis J A Haasbeek; Martijn R Meijerink Journal: Curr Oncol Rep Date: 2022-03-17 Impact factor: 5.945